Artelo Financial Statements From 2010 to 2026

ARTL Stock  USD 1.66  0.05  3.11%   
Artelo Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Artelo Biosciences' valuation are provided below:
Artelo Biosciences does not presently have any fundamental signals for analysis.
Check Artelo Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artelo Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Artelo financial statements analysis is a perfect complement when working with Artelo Biosciences Valuation or Volatility modules.
Check out the analysis of Artelo Biosciences Correlation against competitors.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.

Artelo Biosciences Company Shares Owned By Insiders Analysis

Artelo Biosciences' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

 = 

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current Artelo Biosciences Shares Owned By Insiders

    
  0.47 %  
Most of Artelo Biosciences' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Artelo Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition

Based on the latest financial disclosure, 0.47% of Artelo Biosciences are shares owned by insiders. This is 96.9% lower than that of the Pharmaceuticals sector and 96.69% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 95.34% higher than that of the company.

Artelo Biosciences Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Artelo Biosciences's current stock value. Our valuation model uses many indicators to compare Artelo Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Artelo Biosciences competition to find correlations between indicators driving Artelo Biosciences's intrinsic value. More Info.
Artelo Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Artelo Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Artelo Biosciences Financial Statements

Artelo Biosciences investors utilize fundamental indicators, such as revenue or net income, to predict how Artelo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. Artelo Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Artelo Biosciences is a strong investment it is important to analyze Artelo Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Artelo Biosciences' future performance. For an informed investment choice regarding Artelo Stock, refer to the following important reports:
Check out the analysis of Artelo Biosciences Correlation against competitors.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.